Key Insights

Highlights

Success Rate

100% trial completion (above average)

Treatment Research

6 treatments under study, led by Arm 4 Placebo 100 Mg

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 30/100

Termination Rate

0.0%

0 terminated out of 2 trials

Success Rate

100.0%

+13.4% vs benchmark

Late-Stage Pipeline

50%

1 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed with results

Key Signals

100% success

Data Visualizations

Phase Distribution

2Total
Not Applicable (1)
Phase 4 (1)

Trial Status

Recruiting1
Completed1

Trial Success Rate

100.0%

Benchmark: 86.6%

Based on 1 completed trials

Clinical Trials (2)

Showing 2 of 2 trials
NCT07302880Not ApplicableRecruiting

The Acute Interference of Biotin in Blood Analysis

NCT03995277Phase 4Completed

Effect of Biotin on Routine Laboratory Values

Showing all 2 trials

Research Network

Common Treatments

  • Arm 4 Placebo 100 Mg1
  • Overall To Evaluate The Acute Effect Of Biotin Intake On Streptavidinbased Laboratory Assays During The Hours Immediately Following Consumption1
  • Arm 1 10 Mg Placebo1
  • Biotin1
  • Arm 3 100 Mg Placebo1

Active Sponsors

  • Dr. med. Mahir Karakas1
  • University of Copenhagen1
  • Bispebjerg Hospital1

Top Investigators

Related Conditions

  • Biotin Ingestion2
  • Blood Sample1

Activity Timeline